Heparin and Warfarin in Pregnancy
Samwel Mikaye, CEO of SaMik Medical Center, posted on LinkedIn:
”HEPARIN AND WARFARIN IN PREGNANCY
Anticoagulation may be necessary in pregnancy for conditions like mechanical heart valves, thrombophilia, or previous thromboembolism.
Key principle: Choose an anticoagulant that protects the mother without harming the fetus.
1. HEPARIN
Types
• Unfractionated heparin (UFH)
• Low molecular weight heparin (LMWH) – e.g., Enoxaparin, Dalteparin
Safety
• Does NOT cross the placenta → safe for the fetus
• Preferred anticoagulant in pregnancy, especially in the first trimester
Administration
• UFH: Subcutaneous or IV, frequent monitoring (aPTT)
• LMWH: Subcutaneous, fixed or weight-based dosing, less monitoring needed
Adverse Effects
• Maternal bleeding
• Heparin-induced thrombocytopenia (HIT) – rare with LMWH
• Osteoporosis (with prolonged UFH use)
2. WARFARIN
Safety
• Crosses the placenta → teratogenic
• Avoid in the first trimester due to risk of warfarin embryopathy (nasal hypoplasia, limb defects)
• Risk of fetal bleeding and CNS abnormalities in later trimesters
When Warfarin May Be Used
• In selected high-risk women with mechanical heart valves, after the first trimester, if benefits outweigh risks
• Usually switched to heparin during weeks 6–12, then back to warfarin until near delivery
Monitoring
• Maternal INR target: 2.0–3.0 (varies with valve type)
• Close fetal monitoring recommended
3. MANAGEMENT PRINCIPLES
• First trimester: Prefer LMWH or UFH
• Second trimester: Warfarin may be considered if necessary
• Near term: Switch back to heparin to reduce the risk of fetal bleeding at delivery
• Always coordinate with obstetrics and hematology
KEY POINTS
• Heparin (UFH or LMWH) is safe in all trimesters; does not cross placenta
• Warfarin is teratogenic, especially in the first trimester, and causes fetal bleeding
• Careful switching strategy is required for women with mechanical heart valves
• Close maternal and fetal monitoring is essential”

Stay updated with Hemostasis Today.
-
Jun 6, 2026, 17:39Kalyan Roy: Immunomodulation after Blood Transfusion
-
Jun 6, 2026, 17:37Intissar Haddiya: Can Low-Dose Rivaroxaban Improve Cardiovascular Outcomes in Patients with Advanced CKD?
-
Jun 6, 2026, 17:34Stanley Anokye: From Microcytes and Macrocytes to Target Cells
-
Jun 6, 2026, 16:53Leonardo Roever: Can a Simple Cholesterol Ratio Predict Post-Stroke Depression?
-
Jun 6, 2026, 16:21Abdulkader Jamal Eddin: ABO Blood Group, COVID-19 and Early Respiratory Outcomes in Acute PE
-
Jun 6, 2026, 15:26Yuying Zhang: Grateful to Present on CD44 as A Potential Plasma-Independent Alternative to IVIG in ITP
-
Jun 6, 2026, 15:16Don Deyo: Breakthrough Therapy for Post-Stroke Upper Limb Impairment Now Published
-
Jun 6, 2026, 15:14Julianne Chong: Components of Antithrombotic Stewardship Programs from an International Perspective
-
Jun 6, 2026, 15:13Vincent Ten Cate: The Largest Blood-Based EWAS of Atherosclerosis to Date